tirzepatide serena williams Fronts Campaign for Weight Loss Drugs Serena Williams Is the Latest

Tirzepatide for Weight Loss: Dual-Pathway GLP-1 Treatment from $399/Month Tirzepatide is the active ingredient in Mounjaro and Zepbound the next-generation weight loss medication that targets both GLP-1 and GIP receptors

The proposed direct vascular mechanisms, supported by preclinical and clinical data, include the following: Endothelial protection: GLP-1 receptor agonists promote nitric oxide production, vasodilation, and angiogenesis while inhibiting oxidative stress in vascular endothelial cells Plaque stabilization: Reduced matrix metalloproteinase activity prevents fibrous cap degradation

The drug's manufacturer has also provided some guidance to minimise the triggers for inflammation

This is particularly stressed in the latest consensus report by the ADA and EASD, 56 in which GLP-1 RAs are generally recommended as the first injectable therapy and the presence of heart disease, kidney disease and obesity are co-factored in the selection of antidiabetic agents